Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer
2015年10月6日 - 9:30PM
ビジネスワイヤ(英語)
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (Ritter
Pharmaceuticals or the Company), a pharmaceutical company
developing novel therapeutic products that modulate the human gut
microbiome to treat gastrointestinal diseases, today announced the
appointment of AnnKatrin Petersen-Jappelli, M.D., M.Sc. as its
Chief Medical Officer.
Michael D. Step, Chief Executive Officer of Ritter
Pharmaceuticals, commented, “The addition of Dr. Petersen-Jappelli
further strengthens Ritter Pharmaceuticals’ management with a
leader who has significant experience in both the biotech and
pharmaceutical industries, with a focus on treating
gastrointestinal diseases. She has proven success in product
development across all development stages and will be an invaluable
asset as we progress with the clinical trials of our lead product
candidate, RP-G28, and work to further expand our product
portfolio. We are excited to have Dr. Petersen-Jappelli join our
team and look forward to the contributions she will make to the
Company.”
Dr. Petersen-Jappelli joins Ritter with 25 years of
pharmaceutical and biotechnology drug development experience.
Formerly, she was with Santarus Inc. where she served as Advisor,
Scientific Research and Clinical Development Leader of rifamycin SV
MMX, a Phase 3 program for Traveler’s Diarrhea. She also worked to
develop a portfolio for the use of rifamycin SV MMX in additional
gastrointestinal diseases. Previously to Santarus Inc, Dr.
Petersen-Jappelli was Vice President of Product Development
(Clinical Development and Regulatory Affairs) at MIGENIX Inc. She
has also held development positions at Pfizer, Agouron
Pharmaceuticals, and Sandoz (Novartis), and currently sits on the
board of Salgomed Inc.
Dr. Petersen-Jappelli commented, “Joining Ritter Pharmaceuticals
is an exciting opportunity to be part of a unique and innovative
company that is working to treat gastrointestinal disease through
the modulation of the gut microbiome. I believe my experience in
product development coupled with my research capabilities will be a
great combination for this role and I look forward to working with
the team as we advance our science, build our product portfolio,
and bring therapeutics to market that have the potential to provide
significant relief to patients suffering from gastrointestinal
diseases.”
Dr. Petersen-Jappelli holds an M.D. from the University of
Lausanne, Medical School Lausanne, Switzerland, and a M.Sc. from
the University of Lausanne, HEC Lausanne, Switzerland.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products
that modulate the human gut microbiome to treat gastrointestinal
diseases. Ritter Pharmaceuticals is advancing human gut health
research by exploring the metabolic capacity of gut microbiota, and
translating the functionality of these microbiome modulators into
safe and effective applications. The Company’s lead drug candidate,
RP-G28, has the potential to become the first FDA-approved drug for
lactose intolerance, a condition that affects more than one billion
people worldwide.
Forward-Looking Statements
This release may contain forward-looking statements, which
express the current beliefs and expectations of Ritter
Pharmaceuticals’ management. Such statements involve a number of
known and unknown risks and uncertainties that could cause the
company’s future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Any
statements contained herein that do not describe historical facts,
including but not limited to, statements regarding Dr.
Jappelli-Petersen’s expected contributions to Ritter
Pharmaceuticals as Chief Medical Officer, are forward-looking
statements that involve risks and uncertainties that could cause
actual results to differ materially from those discussed in such
forward-looking statements. These forward-looking statements are
made only as of the date hereof, and the company undertakes no
obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151006005937/en/
For Ritter Pharmaceuticals, Inc.Investors:David Burke,
646-536-7009dburke@theruthgroup.comorMedia:Eric Kim,
646-536-7023ekim@theruthgroup.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 9 2024 まで 10 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 10 2023 まで 10 2024